In the spotlight: a novel CD37 antibody-drug conjugate

Blood. 2013 Nov 14;122(20):3397-8. doi: 10.1182/blood-2013-09-526384.

Abstract

In this issue of Blood, Deckert et al make a strong argument in favor of IMGN529, a novel anti-CD37 maytansinoid antibody-drug conjugate (ADC), elegantly showing its activity against B-cell lymphoma in in vitro and in vivo preclinical studies.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antigens, Neoplasm / immunology*
  • B-Lymphocytes / drug effects*
  • Female
  • Humans
  • Immunotoxins / therapeutic use*
  • Maytansine / analogs & derivatives*
  • Maytansine / therapeutic use
  • Molecular Targeted Therapy*
  • Tetraspanins / immunology*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, Neoplasm
  • CD37 protein, human
  • Immunotoxins
  • Tetraspanins
  • Maytansine
  • naratuximab emtansine